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Abstract
Modern treatment strategies have improved the prognosis of childhood ALL; however, treatment still fails in 25–30% of
patients. Further improvement of treatment may depend on the development of targeted therapies. mTOR kinase, a central
mediator of several signaling pathways, has recently attracted remarkable attention as a potential target in pediatric ALL.
However, limited data exists about the activity of mTOR. In the present study, the amount of mTOR activity dependent
phospho-proteins was characterized by ELISA in human leukemia cell lines and in lymphoblasts from childhood ALL
patients (n = 49). Expression was measured before and during chemotherapy and at relapses. Leukemia cell lines exhibited
increased mTOR activity, indicated by phospho-S6 ribosomal protein (p-S6) and phosphorylated eukaryotic initiation factor
4E binding protein (p-4EBP1). Elevated p-4EBP1 protein levels were detected in ALL samples at diagnosis; efficacy of
chemotherapy was followed by the decrease of mTOR activity dependent protein phosphorylation. Optical density (OD) for
p-4EBP1 (ELISA) was significantly higher in patients with poor prognosis at diagnosis, and in the samples of relapsed
patients. Our results suggest that measuring mTOR activity related phospho-proteins such as p-4EBP1 by ELISA may help to
identify patients with poor prognosis before treatment, and to detect early relapses. Determining mTOR activity in leukemic
cells may also be a useful tool for selecting patients who may benefit from future mTOR inhibitor treatments.
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Introduction
Acute lymphoblastic leukemia (ALL) is the most common
malignant disease diagnosed in children, representing nearly one
third of all pediatric malignancies. The annual incidence of acute
lymphoblastic leukemia is approximately 4–5 cases per 100 000 of
the childhood population, with a pjavascript:showcontent (‘active’,
‘references’); eak incidence in children aged between 1–6 years
[1,2]. Modern treatment strategies consisting of intensive chemo-
therapy, cranial and/or testicular irradiation and stem cell
transplantation have remarkably improved the prognosis of
childhood ALL [3]. However, patients with good survival chances
are at risk of severe acute and late adverse effects of therapy [4],
and treatment still fails in 25–30% of patients. Targeted therapy is
one of the possibilities to improve survival rates [5,6].
Several signal transduction pathways (PI3K/AKT/mTOR,
JAK/STAT, ABL tyrosine kinase, SRC family of tyrosine kinases
and NOTCH1) play a role in normal B- and T-cell development,
proliferation, survival and activation [5]. Deregulation of these
networks is likely to be a key event in leukemogenesis [7].
Recently, mTOR (mammalian target of rapamycin) has gained
remarkable attention as a potential target in different tumor types,
including hematological malignancies [8,9]. The mTOR serine-
threonine kinase is a central mediator of several signal trans-
duction pathways, and it is considered a regulator of cell
proliferation, protein translation and survival [10,11]. mTOR is
able to form two distinct complexes (mTORC1 and mTORC2)
[12], which can be activated by various growth factors, cytokines
and nutrients. The mTORC1 complex is sensitive to currently
used mTOR inhibitors (MTIs: rapamycin and rapalogs). Activated
mTORC1 phosphorylates two key translational regulators:
eukaryotic initiation factor 4E binding protein (4EBP1) [13] and
70 kDa S6 ribosomal protein kinase (p70S6K) [14]. mTORC2
works in concert with PDK1 to phosphorylate/activate AKT;
however, the function and regulation of mTORC2 and its
response to rapamycin remains unclear, and may vary in different
cell types [15,16].
Mechanisms which contribute to increased mTOR activity in
ALL may be the activation of PI3K/AKT by mutations of the
tumor suppressor gene PTEN [17], and by abberant signals from
TCL1, BCR-ABL, growth factor receptors (such as IGF-1R and c-
kit), IL-7R, flt-3 [18,19,20,21,22] and oncogenic NOTCH1, the
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latter one specifically in T-ALL. Inactivation of the FBW7
ubiquitin ligase – which is important for the degradation of
mTOR – was also found in 20% of T-ALLs [23].
Anti-neoplastic properties of MTIs were noted shortly after their
discovery, nevertheless, they were most widely used as immuno-
suppressive agents for a long time. MTIs have been introduced
into oncological therapy only in recent years. Temsirolimus can be
used for the treatment of metastatic renal cell carcinoma [24] and
relapsed or refractory mantle cell lymphoma [25]. Significant
preclinical evidence has been accumulated about mTOR in-
hibition as a feasible therapeutic strategy in several other types of
human solid cancers [26] and in lymphoid malignancies [27,28],
including ALL [29,30].
The mTOR pathway would therefore be an attractive
therapeutical target in childhood ALL as well. In order for this,
we need to find markers which help determine the activation level
of the pathway, and could predict response to mTOR inhibitor
therapy – possibly by using easily applicable, quantitative, routine
diagnostic methods.
The aim of our study was to determine mTOR activity in
childhood ALL cells (cell lines, and leukemia cells isolated at
diagnosis and during treatment). mTOR activity was character-
ized by measuring the phosphorylated form of two mTOR
dependent proteins (p-4EBP1 and p-S6). Differences in mTOR
activity were compared to the immunophenotype of ALL (BCP-
[B-cell progenitor-] or T-ALL) and clinical response to treatment
(good and poor prognosis). mTOR activity was monitored during
treatment, and we sought to determine its role in treatment
response evaluation and as a prognostic factor. The effect of
rapamycin treatment alone, and rapamycin combined with
different chemotherapeutic agents was also investigated in vitro in
ALL cell lines and in cells isolated from childhood ALL patients.
Materials and Methods
Ethics Statement
Samples were obtained with informed consent and all protocols
were approved by the Institutional Ethical Review Board (TUKEB
– Scientific and Reserach Ethics Council, Hungary – no. 53/2011).
Written informed consent was obtained from the parents on behalf
of the children participants involved in our study.
Patients
Initially, peripheral blood and bone marrow samples (n = 269)
were collected from children with ALL. Diagnosis was based on
clinical findings, cytomorphology, flow cytometry, cytogenetics
and molecular genetic analyses of blasts, according to the
treatment protocol. Some of the samples were inadequate for
measurements and statistical analysis because of the low number of
isolated lymphoblasts. Samples from all phases of treatment
(collected at diagnosis, and at conventional response checkpoints
[at days 15, 33, and 3 months after the beginning of therapy]) were
available from 21 patients; additional samples were analysed at
diagnosis from 28 other patients (from these patients, samples were
obtained at relapse, where applicable), and from one patient only
at relapse. Bone marrow samples from 42 children with BCP-ALL,
from 8 children with T-ALL, and from non-leukemic patients
were used for further examination. Five patients died during the
follow up period: four patients due to the progression of the
disease, and one patient due to transplant related toxicity.
Eventually, appropriate samples from 49 children (15 females
and 34 males) with primary ALL were examined and data was
subjected to statistical analysis. Average age at diagnosis was 6.6
years (range 1.8–16.4 years); 59% of the patients belonged to the
group with favorable prognosis, based on their age (6 years or less).
An initial WBC count of 20 G/l is the cutoff level for defining
different prognostic groups according to our treatment protocol;
based on this, 57% of the patients had better prognosis, with the
initial WBC count being less than 20 G/l.
Cytogenetic and molecular genetic karyotyping of the blasts
revealed the following alterations: a. 2 patients possessed
a Philadelphia chromosome (t[9;22], BCR/ABL); ABL amplifica-
tion was detected in one patient, and RUNX1 amplification was
seen in one patient – these genetic lesions indicate an unfavorable
prognosis for these patients, all of whom (n= 4) were treated
according to the high risk (HR) arm of the protocol; b. 19 patients
with hiperdiploidy and two patients with ETV6/RUNX1 fusion
were assigned to the group with considerably good prognosis
(termed hyperdiploid group; n= 21); c. karyotyping revealed
genetic lesions irrelevant to prognosis, or no genetic alterations
in 25 patients (termed normal karyotype group; n= 25).
Lymphoblasts derived from bone marrow and peripheral blood
were both used and compared to each other in experiments in
order to define mTOR signaling pathway activity. Clinical data
were collected prospectively from the date of diagnosis. All
relevant clinical and laboratory data of the 49 patients are
summarized in Table 1. Most ALL patients were treated
according to the ALL IC-BFM 2002, two patients according to
the ALL IC BFM 2009, one patient according to the ALL BFM 95
protocol. According to the prognostic factors described in
treatment protocols, patients received different intensities of
therapy: 21 (42%) children were treated in the standard risk arm
(SR), 19 (39%) in the intermediate risk arm (IR) and 9 (19%) in the
high risk arm (HR) of the protocol.
Prognosis was evaluated in all 49 patients accordingly, based on:
1. WBC count at diagnosis, age, prednisolone response at day 8
(absolute blast cell count in peripheral blood), bone marrow blast
percentage on day 15 and on day 33; and 2. relapse during long-
term follow-up – patients with good prognosis were in remission
during the observation period, and some patients with initially
good prognosis relapsed or progressed during this time period,
regardless of evaluation based on criteria in point 1. Three such
patients were initially in the good prognostic group, but relapsed
during follow-up. Therefore, these patients were reassigned later to
the poor prognostic group, such that the final number of patients
in this group was 12 at statistical analysis. The samples and data of
patients were collected in the time period of 2006–2012.
Primary ALL Cells, Cell Lines and Culture Conditions
Lymphoblasts were isolated from bone marrow and peripheral
blood samples of childhood ALL patients and healthy/non-
leukemic individuals by ficoll gradient centrifugation (Histopaque
1077, Sigma Aldrich, St. Louis, MO). Normal B-cells and T-cells
were obtained by MACS CD19 micromagnetic beads (Miltenyi
Biotec, Auburn, CA) and by nylon wool fiber (Wako Chemicals),
respectively. Isolated cells were stored at 270uC or short-term
cultured.
Previously characterized human ALL cell lines (Nalm6– B-cell
precursor leukemia, clone ACC 128, German Tissue Collection of
Microorganisms and Cell Culture [DSMZ]; Mn60– B-cell
leukemia established from acute B-ALL, clone ACC138, DSMZ;
Jurkat – acute T cell leukemia, clone E6-1, American Type
Culture Collection [ATCC]; CCRF-CEM –acute T lymphoblastic
leukemia, clone #82112105, European Collection of Cell Culture
[ECACC]); and a Hodgkin-lymphoma cell line (KMH2, clone
ACC8, DSMZ) were used for in vitro experiments.
Lymphoblasts and cell lines were cultured in RPMI 1640
Medium (Sigma), supplemented with 10–20% fetal calf serum
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(FCS, Sigma), 0.03% L-glutamine and antibiotics (Sigma) at 37uC
in a 5% CO2 humidified atmosphere. Cells were cultured on 24-
well plates or in 25 cm2 flasks (2–46105 cells/ml), and treated for
0–72 hours with the following chemotherapeutic agents: rapamy-
cin (Rapamycin, Sigma), methotrexate (Methotrexate, Teva,
Pharmachemie BV), cytosine arabinoside (Alexan, Ebewe
Pharma), doxorubicin (Doxorubicin, Ebewe Pharma), vincristine
(Vincristin liquid, Richter Gedeon), etoposide (Etoposide, Teva,
Pharmachemie BV), methylprednisolone (Methyl-prednisolon-
Human, TEVA) and cyclophosphamide (Endoxan, Baxter On-
cology). Each cell line was cultured and exposed to drugs in
triplicates in at least 3 independent experiments. Cell morphology
was evaluated on methanol fixed and hematoxylin-eosin (HE)
stained cytospin preparates (59 500 rpm).
Apoptosis Detection by Flow Cytometry
Apoptosis measurements were performed according to Mihalik,
et al [31]. Briefly, cells were fixed in 70% ethanol (at 220uC),
followed by alkalic extraction (200 mM Na2HPO4, pH 7.4),
addition of 100 mg/mL RNase (Sigma) and propidium iodide
staining (95–98%, Sigma). Membrane permeabilization and
alkalic extraction allow the release of small molecular weight
DNA fragments from apoptotic cells, and the apoptotic population
becomes easily detectable as the subG1 fraction on histograms
[32]. Apoptosis measurements were performed on a FACSCalibur
Table 1. Summary of clinical data and mTOR activity related p-4EBP1 in 49 primary ALL patients.
low mTOR activity1 high mTOR activity1 P value
number (%) number (%) number (%)
Total 49 (100%) 39 (79%) 11 (21%)
Age
6 years or less 29 (59%) 23 (79%) 6 (21%) 0.722x
6 years , 20 (41%) 15 (75%) 5 (25%)
Gender
female 15 (31%) 14 (93%) 1 (7%)
male 34 (69%) 24 (71%) 10 (29%) 0.137Q
Cell type
pre-T 8 (16%) 4(50%) 4 (50%)
pre-B 41 (84%) 34 (83%) 7 (17%) 0.063Q
Steroid response,p
response at day 8 40 (81%) 35 (88%) 5 (12%)
no response at day 8 9 (19%) 3 (33%) 6 (67%) ,,0.05Q
WBC count
20 G/l. 21 (43%) 17 (81%) 4 (19%)
20 G/l, 28 (57%) 21 (75%) 7 (25%) 0.737Q
Karyotype*,p
normal 24 (49%) 24 (71%) 7 (29%)
hyperdiploid 21 (43%) 20 (95%) 1 (5%) ,0.05x
high risk genetic lesion 4 (8%) 1 (25%) 3 (75%)
Prognosis#,p
good 37 (76%) 33 (89%) 4 (11%) ,,0.05Q
poor 12 (24%) 4(33%) 8 (67%)
Present statusp
disease free remission in
SR group 21 (43%) 20 (95%) 1 (5%)
IR group 16 (33%) 13 (81%) 3 (19%)
HR group 5 (10%) 3 (60%) 2 (40%) ,,0.05x
remission (after relapse or TX) 3 (6%) - 2 IR; 1HR 2 (67%) 1 (33%)
death (after progression or TRM) 4 (8%) - 1 IR; 3HR 0 (0%) 4 (100%)
1cutoff equals 1.1 (OD p-4EBP1 ELISA).
*based on cytogenetic and molecular genetic analysis; the hyperdiploid group also includes two cases with ETV6/RUNX1 fusion (good prognosis). High risk genetic
lesions are: BCR/ABL fusion (two cases), ABL amplification (one case) and RUNX1 amplification (one case).
#based on steroid response and current status; see methods: SR - standard, IR - intermediate, HR - high risk arm of the therapy; TX – transplantation, TRM -
transplantation related mortality.
Q– Fisher’s exact probability and,
x- chi2 tests.
p- significant correlation with mTOR activity level.
doi:10.1371/journal.pone.0059335.t001
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flow cytometer (BD Biosciences) using Cell Quest software (BD
Biosciences); 10–20 000 events were collected for each sample.
Data was analyzed with WinList software (Verity Software House).
ELISA Analysis
Cell lysates were obtained from isolated bone marrow or
peripheral blood derived ALL cells, isolated normal lymphoid cells
and cell lines, in Cell Lysis Buffer (Cell Signaling) containing
1 mM phenyl-methylsulfonyl fluoride (PMSF) for 30 minutes on
ice (1 M cells/sample/100 ml Lysis Buffer). Protein concentration
was determined by QubitH fluorometry (Invitrogen) to ensure
equal cell numbers. Samples with significantly lower or higher
protein concentrations were not involved in this study; mean
protein concentration of analyzed samples was 16.460.15 mg/ml.
Sandwich ELISA Kits (PathScan p-4EBP1 - Thr37/Thr46 and
PathScan p-S6 Ribosomal Protein - Ser235/236, Cell Signaling)
were used for the detection of p-4EBP1 and p-S6 ribosomal
protein, according to the manufacturer. Absorption and optical
density (OD) were measured at 450 nm wavelength. A p-4EBP1
and p-S6 overexpressing cell line (KMH2) was used as a positive
control.
Several methods were tested to investigate the amount of
mTOR kinase activity related proteins in blood and bone marrow
samples of ALL patients. Different ELISA kits requiring lower cell
numbers were tested to analyze and compare various samples. The
p-4EBP1 ELISA kit mentioned above was the most reliable one.
Data obtained with this assay correlated well with Western blotting
results, and showed reduced mTOR activity after in vitro
rapamycin treatment in cell lines (data not shown). Moreover,
this assay was more sensitive than p-S6 ELISA, even though p-S6
is the most commonly used marker for mTOR activity in
immunohistochemistry.
Immunocytochemistry
Cytospin preparates were incubated with primary antibodies
(anti-phospho-S6 and anti-phospho-mTOR, 1:100 and 1:50,
respectively; Cell Signaling) after endogenous peroxidase blocking.
Immunodetection was performed by Novolink detection system
(Novocastra), visualized by DAB (Dako) and counterstained with
haematoxylin. p-4EBP1 and p-S6 immunostaining was also
performed in liquid phase and measured by flow cytometry:
2 M cells/sample were labeled with 2 ml anti-phospho-S6 or anti-
p-4EBP1 antibody (Cell Signaling), followed by biotinylated anti-
rabbit IgG secondary antibody (Vector Laboratories) and Qdot
705 streptavidin conjugate (Invitrogen). Measurements were
performed on a FACSCalibur flow cytometer (BD Biosciences)
with CellQuest Pro software; 10–20 000 events were collected for
each sample. The differences between mean fluorescence in-
tensities (MFI) of unstained negative control cells, and samples
stained with anti-p4EBP1 or p-S6 analyzed in parallel were
calculated using CellQuest Pro software (BD Biosciences).
Statistical Analysis
Mean arithmetic values (x) and standard deviation (SD) of the
data were calculated. Variables were compared with Student’s t-
test if sample distribution was normal, or Mann-Whitney U test if
sample distribution was asymmetrical. The cutoff point for ELISA
OD – which segregates patients into good and poor prognostic
groups with appropriate specificity and sensitivity – was calculated
by ROC curve analysis. Categorical data were compared using
chi2 test and Fisher’s exact probability test to evaluate significance.
Overall survival analyses were done using the Kaplan-Meier
method. Survival intervals were determined as the time period
from initial diagnosis to the time of death (overall survival) or
relapse (relapse free survival). Survivals of groups stratified by p-
4EBP1 levels – indicating mTOR activity – was compared with
the log-rank test. Multivariate analysis of different prognostic
factors was done using the Cox regression model.
P,0.05 was considered statistically significant. Statistical
analysis was performed with Statistica 9.0 (Statsoft, Tulsa, OK)
and SPSS software.
Results
P-S6 and p-4EBP1 are Over-expressed in Leukemia Cells
The expression of the mTOR pathway targets p-S6 and p-
4EBP1 was characterized in human acute lymphoblastic leukemia
cells and normal lymphoid cells by ELISA. (The KMH2 cell line
was used as a positive control [p-4EBP1 OD: 2.860.01; pS6 OD:
0.3760.02].) The value for normal lymphoid cells was considered
to be 100% (or 1) for comparisons. The amount of activated
mTOR targets was not significantly different in peripheral blood
mononuclear cells (PMNC) and bone marrow mononuclear cells
(BMMNC) within the same healthy individuals or ALL patients
investigated (Fig. 1a). Leukemia and lymphoma cell lines (Nalm6,
Mn60, Jurkat, CEM and KMH2) showed increased p-S6 (2.4 to
8.5-fold) and remarkably elevated p-4EBP1 (63.5 to 77.6-fold)
levels by ELISA, compared to normal lymphoid cells (isolated
PMNC, T- and B-cells). Similarly to cell lines, p-4EBP1 and p-S6
expression was significantly elevated in ALL samples (both PMNC
and BMMNC) at diagnosis, compared to normal lymphoid cells
(Fig. 1b, Fig. 2a). However, upregulation of pS6 was less
pronounced.
P-4EBP1 and/or p-S6 levels were also analyzed by immuno-
cytochemistry on cytospin slides (n = 7) and by flow cytometry
(n = 3) in ALL samples. Elevated mTOR activity was detected in
ALL blasts with both stainings, compared to normal peripheral
mononuclear cells. ALL cells showed moderate or strong
expression, evaluated by two independent cytopathologists;
however, normal cells were scored negative or only weak
expression was detected on cytospin slides (Fig S1). Flow
cytometric analysis also revealed high p-4EBP1 and p-S6 staining
in all three examined ALL samples: mean fluorescent intensity
(DMFI) was 15–20 fold compared to non-leukemic control samples
(Fig. 2b).
Correlation of p-4EBP1 Expression at Diagnosis with
Prognosis/Response to Therapy and other Clinical Data
The expression level of p-4EBP1 was analyzed at day 0 in all
primary samples from the 49 different ALL patients. P-4EBP1
level was higher in all ALL samples than in normal PMNC,
isolated B or T-cells. The amount of p-4EBP1 detected by ELISA
was significantly higher at day 0 in the BMMNCs of ALL patients
with poor prognosis – both in B- and T-ALL patients. We
established a cutoff point of OD=1.1 for p-4EBP1 ELISA values,
which segregates ALL patients into good (OD,1.1) and poor
(OD.1.1) prognostic groups (Fig. 2a). The cutoff point with
appropriate specificity (89%) and sensitivity (67%) was calculated
with ROC curve analysis. Samples with p-4EBP1 OD values
higher than 1.1 were considered to have high mTOR activity,
whereas OD,1.1 was considered to represent low mTOR
activity. An OD of 1.1 equals a 27,5-fold increase in p-4EBP1
levels compared to normal lymphoid cells.
Significant statistical correlation was found between poor
prognosis (12 patients), poor steroid response at day 8 (9 patients)
and high levels of mTOR activity related p-4EBP1. Moreover, low
p-4EBP1 levels showed significant correlation with relapse free
survival (present status). A significant correlation between non
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Figure 1. The amount of mTOR activity dependent phospho-proteins (p-4EBP1 and p-S6) in lymphoma/leukemia cells (ELISA). (a.) P-
4EBP1 ODs are shown for normal control peripheral blood mononuclear cells (N1, N2, N3), isolated peripheral normal B- and T-cells (B, T), isolated
peripheral blood mononuclear cells and isolated bone marrow mononuclear cells from non-leukemic patients (NL) and isolated primary childhood
ALL cells from representative patient samples, and from leukemia (Jurkat, CEM, Mn60, Nalm6) and lymphoma cell lines (KMH2). (b.) Relative p-4EBP1
and p-S6 expression was determined in samples from ALL patients (n = 10) and in leukemia/lymphoma cell lines (Jurkat, CEM, Mn60, Nalm6, KMH2);
expression of normal lymphoid cells is considered to be 1. (OD: optical density; MNC: mononuclear cells. Equal cell numbers and equal protein
concentrations were confirmed for comparisons.).
doi:10.1371/journal.pone.0059335.g001
Figure 2. mTOR activity related p-4EBP1 expression in samples of ALL patients with different prognoses (ELISA) and detection of p-
4EBP1 and p-S6 in ALL cells by flow cytometry. (a) P-4EBP1 OD values in 49 ALL samples (n = 37 for patients with good prognosis; n = 12 for
poor prognosis, criteria for prognostic groups are described in the Methods section). P-4EBP1 OD levels were significantly different between patients
with good and poor prognosis (p,0.05). The cutoff value between p-4EBP1 OD values representing high and low mTOR activity was determined to
be 1.1 by ROC curve analysis. (b) p-S6 and p-4EBP1 overexpression is confirmed by flow cytometry in ALL cells. Representative histograms for p-4EBP1
and p-S6 flow cytometric analysis in normal PMNC and in ALL samples. Expression was calculated as the difference between MFIs of p-4EBP1 or p-S6
stained (p-4EBP1 and p-S6, respectively) and parallel unstained controls (-co). Differences between MFIs (DMFI) was 2.35 (pS6) and 1.56 (p-4EBP1) for
normal peripheral mononuclear cells. However, DMFI was 42.6 and 32.4 for p-S6 and p-4EBP1, respectively, in the representative ALL case shown
here.
doi:10.1371/journal.pone.0059335.g002
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hyperdiploid karyotypes and high mTOR activity was also
established. However, no significant association between mTOR
activity and other clinical data (age, gender, cell type and WBC
count) was detected by statistical analysis (Table 1). Next, we used
the Kaplan-Meier method to analyze survival data stratified by p-
4EBP1 levels (indicative of mTOR activity), and we showed
a significant difference in overall survival and relapse free survival
between patients with low and high mTOR activity (Fig. 3).
Multivariate analysis (including standard prognostic variables,
such as age, gender, cell lineage and WBC count) also indicated
that high levels of p-4EBP1 detected by ELISA (.1.1 OD)
predicted poor outcome, i.e. it increased relative risk for relapse/
poor therapeutic response, independently of other variables
(Table 2).
Samples from 21 patients were available for analysis at diagnosis
and during treatment follow-up, which enabled us to monitor
expression changes during therapy and at relapse. P-4EBP1
expression significantly decreased during treatment in all 21
examined ALL cases, with a concomitant reduction in the
percentage of lymphoblasts (0–10% of bone marrow mononuclear
cells). P-4EBP1 expression was reduced in patients with good
prognosis (OD,1.1) after treatment (compared to day 0), and
remained so after two years. However, in the two relapsed patients
examined, we detected high p-4EBP1 expression (OD.1.1) at day
0, which predicted unfavorable prognosis, and this was clinically
confirmed later; in these cases, the expression of p-4EBP1 protein
decreased significantly at day 33, but increased above the initial
level at relapse (Fig. 4a).
Rapamycin Modifies Apoptosis and p-4EBP1 Expression
in ALL Short-term Cultures
Leukemia cell lines and lymphoblasts obtained from bone
marrow samples of ALL patients were kept in short-term culture
and treated with rapamycin (50 ng/ml). Rapamycin monotreat-
ment had only an antiproliferative effect with no apoptosis
induction in Nalm6, Mn60 and CEM cells; however, it induced
apoptosis in Jurkat cells after 72 h treatment (data not shown).
Baseline spontaneous apoptosis was higher in short-term
cultures of primary ALL cells (approaching 30% after 24 h) than
in cell lines; moreover, rapamycin was able to increase apoptosis
significantly in short-term cultures after 24 h treatment in some,
but not all primary isolated ALL lymphoblast cultures. Apoptosis
induction was accompanied by reduced p-4EBP1 expression after
rapamycin treatment. We were able to analyze the apoptotic effect
and p-4EBP1 expression in parallel in four samples treated with
rapamycin for 24 h. Rapamycin did not decrease the expression of
p-4EBP1 in two cases (one isolated from primary ALL and one at
relapse), and apoptosis induction was not significant (,10%
increase in apoptosis). However, rapamycin treatment enhanced
apoptosis significantly (.50% apoptotic cells) in the other two
cases (isolated from primary ALL), accompanied by a concomitant
reduction of p-4EBP1, which was also significant (Fig. 4b).
Rapamycin Enhanced the Apoptotic Effect of
Chemotherapeutic Agents in Leukemia Cell Lines and in
Short-term ALL Cultures
Cell lines and lymphoblasts isolated from 3 primary and 2
relapsed ALL patients were treated with rapamycin combined
with chemotherapeutics (doxorubicin, etoposide, vincristine,
methotrexate and methyl-prednisolone). Rapamycin increased
the apoptotic effect of all tested chemotherapeutics in Nalm6
Figure 3. Survival analysis (Kaplan-Meier curves). Kaplan-Meier curves show overall and relapse free survivals for patients (n = 49) stratified by
mTOR activity. Cutoff value between low and high mTOR activity groups (n = 37 and n=12, respectively) was determined to be 1.1 for p-4EBP1 ODs
(ELISA). We found that patients with low mTOR activity had significantly longer overall and relapse free survival (P,,0.05 with log-rank test; o:
complete event, +: censored cases).
doi:10.1371/journal.pone.0059335.g003
Table 2. Multivariate analysis of various standard
independent prognostic factors in ALL cases.
Prognostic factors RR (95% CI) p
Age in year (,6 versus .6) 0.204 (0.025–1.65) 0.136
Gender (female versus male) na 1
Cell type (B versus T) 5.148 (0.429–61.8) 0.196
WBC (,20 G/l versus .20 G/l) 0.249 (0.025–2.48) 0.236
mTOR activity (low versus high)p 37.07 (2.552–538.51) 0.0081
*Cutoff value is 1.1 p-4EBP1 OD.
RR – relative risk, 95% CI –95% confidence interval.
na – not applicable.
doi:10.1371/journal.pone.0059335.t002
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(Fig. 5a) and Jurkat cells. However, Mn60 and CEM cells were less
sensitive to combination treatment. Rapamycin enhanced apo-
ptosis induced by cytosine arabinoside, etoposide and methyl-
prednisolone in Mn60 cell cultures, whereas it promoted only the
effect of methyl-prednisolone in CEM cells in vitro.
The effect of rapamycin and chemotherapeutic drugs was
variable in BMMNC isolated from ALL samples. In two patients
(one primary and one relapsed), induction of apoptosis was not
significant (,l0%) by rapamycin and the combinations. In other
three cases (2 primary cases and one relapsed), apoptosis induction
Figure 4. Changes in mTOR related p-4EBP1 expression in samples of ALL patients after in vivo chemotherapy and in cultured ALL
cells treated with rapamycin in vitro. (a) P-4EBP1 OD is reduced by chemotherapy, but re-increases during relapse in ALL patient samples. Data is
shown from 2 representative patients with good prognosis and 2 patients with poor prognosis at day 0, day 33, after three months of treatment, and
at relapse (ELISA). (b) In vitro rapamycin sensitivity is variable in different human ALL samples (n = 4). P-4EBP1 levels variably decrease or increase after
in vitro rapamycin treatment (50 ng/ml, 24 h) in isolated ALL cells (ELISA). A decrease in p-4EBP1 was associated with concomitant induction of
apoptosis by rapamycin (.50% apoptotic cells in the first two samples; data not shown). (The first three samples were cultured from cells isolated
from primary ALL cases and one at relapse.) *- P,0.05.
doi:10.1371/journal.pone.0059335.g004
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by rapamycin was significant (22–94%), and rapamycin enhanced
the effect of etoposide, vincristine and methyl-prednisolone
(Fig. 5b).
Discussion
Increased mTOR activity has already been reported and data
has been published about the in vitro apoptotic effects of rapamycin
in cell lines and isolated primary ALL cells [29,33,34]. However,
quantitative analysis of mTOR pathway activity in childhood ALL
patients is lacking. Furthermore, mTOR activity and the amount
of related phosphoproteins has not been determined by ELISA in
human leukemia cells; only one study describes an ELISA-based
method for measuring p-p70S6K as an assessment of mTOR
inhibition in peripheral lymphoid cells from renal allograft
recipients treated with everolimus [35].
In the present study we investigated the activity of the mTOR
pathway by ELISA in bone barrow samples from childhood ALL
patients. The levels of phosphoproteins (p-4EBP1 and p-S6)
related to mTOR activity were determined in normal lymphoid
cells and in isolated lymphoblasts. Several ELISA kits were tested,
and we found that the p-4EBP1 and the p-S6 assays worked
reliably in our study, with the p-4EBP1 kit being the most useful.
Measuring p-4EBP1 is also advantageous because 4EBP1 is
directly phosphorylated – and thus inhibited – by mTOR. In
contrast, S6 protein can be phosphorylated not only through the
Figure 5. Rapamycin increases the apoptotic effect of several chemotherapeutics in leukemia cells in vitro (flow cytometry). (a) The
apoptotic effect of rapamycin (50 ng/ml) combined with other drugs. Nalm6 cells were treated for 72 h. (DOX: doxorubicin, 100 nM; VINC: vincristin,
3 nM; MTX: methotrexate, 20 nM; ARA-C: cytarabine, 10 ng/ml, CYCLO: cyclophosphamide, 500 nM; MED: methyl-prednisolone, 100 nM.) *- p,0,05.
(b) The apoptotic effect of rapamycin (rap, 50 ng/ml) combined with methyl-prednisolone (med; 100 nM), vincristin (vin; 3 nM) and etoposide (eto;
10 nM) treatment in isolated childhood BCP-ALL cells from three different patients, treated for 24 h. (The first two samples were cultured from cells
isolated at diagnosis, the third one at relapse).
doi:10.1371/journal.pone.0059335.g005
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mTOR pathway – by p70S6 kinase –, but also by other signaling
pathways, such as PDK1, MAPKs and stress activated protein
kinase (SAPK) [36].
We found that mTOR signaling pathway activity (indicated by
p-4EBP1 levels) was high in leukemia/lymphoma cell lines and in
bone marrow cells from ALL patients at day 0. The level of
phosphorylated mTOR target proteins – p-4EBP1 and p-S6– fell
back to virtually normal in ALL samples upon response to
chemotherapeutic treatment. In samples of relapsed patients,
mTOR activity increased when the disease reappeared: indeed, p-
4EBP1 expression was above day 0 levels at relapses. Interestingly,
mTOR activity was significantly higher at diagnosis in patients
with poor prognosis than in patients with good prognosis. Using
ROC curve analysis, we established a cutoff point (OD=1.1) for
p-4EBP1 ELISA values, which segregated patients into two
groups: one with high p-4EBP1 levels, and consequently, high
mTOR activity, and another group with low mTOR activity. This
cutoff value can be validated in larger studies, and may serve as
a clinically available prognostic marker for ALL in the future. The
disadvantage of ELISA is that it is time-consuming and requires
relatively large numbers of cells. A more easily applicable method,
such as flow cytometry, might be more useful for the detection of
mTOR activity related phosphoprotein expression at diagnosis or
during follow-up.
It is an important observation that mTOR activity – charac-
terized by p-4EBP1 expression – is not significantly different in
bone marrow and peripheral lymphoid cells from the same
patient. Patients with a greater chance of relapse – who, therefore,
require closer follow-up – may be monitored by measuring
mTOR activity in peripheral blood samples. Several studies focus
on the issue of early detection of disease recurrence, however, an
effective method – which is minimally invasive and shows relapse
very early – does not exist yet.
Several studies have been initiated to investigate the effects of
MTI treatment in childhood ALL [29,8,37], and our in vitro
experiments also confirm the ability of mTOR inhibitors to induce
apoptosis in isolated childhood ALL lymphoblasts. Many clinical
trials have been launched to test the efficacy of mTOR inhibitors
as single agents, particularly in the treatment of relapsed
hematological diseases (eg. everolimus for relapsed/refractory
NHL – phase I; sirolimus for relapsed/refractory ALL/NHL –
phase I) [33]. However, the results of clinical trials in childhood
ALL have not yet been published. Only one abstract reports the
results of a phase I trial with sirolimus in pediatric patients with
relapsed/refractory leukemia. One paper describes the safety of
sirolimus added to graft versus host prophylaxis after allogeneic
hematopoietic stem cell transplantation in childhood ALL in
a phase I/II trial [38]. Another paper reports maximum-tolerated
dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic
and pharmacodynamic properties of everolimus in children with
refractory or recurrent solid tumors in a phase I trial [39].
Instead of focusing on the effect of mTOR inhibitors as single
therapeutic agents, the combination of mTOR inhibitors and
conventionally used chemotherapeutic drugs (such as dexameth-
asone, doxorubicin, etoposide, vincristine and asparaginase) is
currently being investigated more closely [37,40,41,42]. Combi-
nation treatments with mTOR inhibitors are much more effective
in inducing apoptosis, which is also supported by our study; the
combination with methyl-prednisolone being the most effective,
not only in cell lines but also in ALL samples. ALL patients
frequently develop steroid resistance at relapse, and sirolimus has
been reported to restore steroid sensitivity in steroid-resistant ALL
[43,44]. Correspondingly, we found that methyl-prednisolone
combined with rapamycin induced significant apoptosis in isolated
lymphoblasts in one ALL case after relapse.
It is important to note that the combination of rapamycin and
various cytotoxic drugs may be more effective in vivo than in vitro,
which may be explained by the modifying effects of the
microenvironment. Combination treatments are also being
examined in several clinical trials, mainly in relapsed hematolog-
ical malignancies (acute myeloid leukemias and high risk
lymphomas) [33,25,24].
Our results raise an important question: what selection criteria
should be used for identifying ALL patients who may benefit from
MTI therapies? Should we decide based on resistance to
chemotherapy, the occurrence of relapse, or high pre-treatment
mTOR activity? We suggest that patients with poor prognosis may
be identified by measuring p-4EBP1 levels at diagnosis; further
markers will be required for predicting the potential response to
rapamycin treatment for individual patients within this group.
Indeed, it must be kept in mind that high basal mTORC1 activity
does not necessarily mean that the patient will respond to MTIs
[45]. Our results demonstrate that in vitro rapamycin treatment
does not necessarily result in the decrease of mTOR activity in
ALL cells in all cases. The background of resistance to MTIs is not
yet clear, but an increase in mTORC2 activity, and a shift in the
proportion of mTORC1/C2 complexes must be considered. Dual
inhibitors (inhibiting both mTORC1 and mTORC2 complexes)
may be a solution for mTOR inhibition in rapamycin resistant
cases, and promising experimental results have been published
about their effect in leukemia cells [46,47].
We showed that the activity of mTOR signaling is increased in
childhood ALL lymphoblasts, and the level of activity can be
monitored by p-4EBP1 ELISA. This may prove a useful method
for selecting patients with poor prognosis at an early phase of the
treatment. Patients with lymphoblasts exceeding a given level of
mTOR activity may require closer follow-up, due to a significantly
increased risk of relapse. The impact of mTOR activity on the
survival capacity of ALL cells was also confirmed in vitro, which
could be exploited by combining mTOR inhibitors with other
therapeutic modalities.
Conclusions
We determined the amount of mTOR activity related
phosphoproteins in childhood ALL patients by ELISA. We
suggest that the presence of these proteins (p-4EBP1 and p-S6)
may serve as an early marker of prognosis, as patients with poor
prognosis showed significantly higher p-4EBP1 level at diagnosis
than patients with good prognosis. We established a cutoff value
for p-4EBP1 ELISA OD levels, which may help segregate patients
into good and poor prognostic groups. Early screening may also
identify high risk patients and provide targets for therapy. We also
found that mTOR activity was increased at relapse, and the
detection of this increase may help in designing treatment and
follow-up.
Taken together, our results provide a basis for further in vitro
and in vivo studies for determining exact selection criteria for
childhood ALL patients who may benefit from MTI therapy.
Supporting Information
Figure S1 High p-S6 expression is confirmed by immunocyto-
chemistry in samples of ALL patients. Representative p-S6
staining in isolated bone marrow mononuclear cells of an ALL-
and a non-leukemic patient (immunocytochemistry; 400x).
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